Literature DB >> 3486471

Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II.

P J Fay, Y Kawai, D D Wagner, D Ginsburg, D Bonthron, B M Ohlsson-Wilhelm, S I Chavin, G N Abraham, R I Handin, S H Orkin.   

Abstract

The generally mild bleeding disorder of von Willebrand disease is associated with abnormalities of two distinct plasma proteins, the large multimeric von Willebrand factor (vWF), which mediates platelet adhesion, and von Willebrand antigen II (vW AgII), which is of unknown function. The two proteins were found to have a common biosynthetic origin in endothelial cells and megakaryocytes, which explains their simultaneous absence in the severe form of this hereditary disease. Shared amino acid sequences from a 100-kilodalton plasma glycoprotein and from vW AgII are identical to amino acid sequences predicted from a complementary DNA clone encoding the 5' end of vWF. In addition, these proteins have identical molecular weights and immunologic cross reactivities. Monoclonal antibodies prepared against both proteins recognize epitopes on the pro-vWF subunit and on a 100-kilodalton protein that are not present on the mature vWF subunit in endothelial cell lysates. In contrast, polyclonal antibodies against vWF recognize both pro-vWF and vWF subunits. Thus, the 100-kilodalton plasma glycoprotein and vW AgII are identical proteins and represent an extremely large propolypeptide that is first cleaved from pro-vWF during intracellular processing and then released into plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486471     DOI: 10.1126/science.3486471

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

1.  Exponential size distribution of von Willebrand factor.

Authors:  Svenja Lippok; Tobias Obser; Jochen P Müller; Valentin K Stierle; Martin Benoit; Ulrich Budde; Reinhard Schneppenheim; Joachim O Rädler
Journal:  Biophys J       Date:  2013-09-03       Impact factor: 4.033

2.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Nucleotide sequence of pre-pro-von Willebrand factor cDNA.

Authors:  D Bonthron; E C Orr; L M Mitsock; D Ginsburg; R I Handin; S H Orkin
Journal:  Nucleic Acids Res       Date:  1986-09-11       Impact factor: 16.971

4.  Invertebrate vitellogenin is homologous to human von Willebrand factor.

Authors:  M E Baker
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

Review 5.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

6.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease.

Authors:  B B Shelton-Inloes; F F Chehab; P M Mannucci; A B Federici; J E Sadler
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

7.  Inheritance and prevalence of von Willebrand's disease severe form in a Brazilian population.

Authors:  R R Fischer; C Lerner; E Bandinelli; A S Fonseca; I Roisenberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

8.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

9.  The role of the 5'-flanking region in the cell-specific transcription of the human von Willebrand factor gene.

Authors:  V Ferreira; Z Assouline; J L Schwachtgen; B R Bahnak; D Meyer; D Kerbiriou-Nabias
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

10.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.